Xenetic Biosciences, Inc.
XBIO
$4.11
-$0.17-3.97%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -18.13% | 5.30% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.13% | 5.30% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -18.13% | 5.30% | |||
| SG&A Expenses | 66.82% | 5.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.70% | -5.78% | |||
| Operating Income | -93.53% | 19.41% | |||
| Income Before Tax | -103.70% | 21.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -103.70% | 21.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -103.70% | 21.19% | |||
| EBIT | -93.53% | 19.41% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -103.41% | 25.00% | |||
| Normalized Basic EPS | -103.45% | 25.00% | |||
| EPS Diluted | -103.41% | 25.00% | |||
| Normalized Diluted EPS | -103.45% | 25.00% | |||
| Average Basic Shares Outstanding | 0.14% | 5.10% | |||
| Average Diluted Shares Outstanding | 0.14% | 5.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||